Skip to content

A multicenter, randomized, double-blind, placebo-controlled trial for Lu-Dang-Shen oral liquid in the treatment of reduced digestion function of convalescent new coronavirus pneumonia (COVID-19) patient

A multicenter, randomized, double-blind, placebo-controlled trial for Lu-Dang-Shen oral liquid in the treatment of reduced digestion function of convalescent new coronavirus pneumonia (COVID-19) patient

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003304
Enrollment
Unknown
Registered
2020-05-15
Start date
2020-05-08
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Wuhan Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of the n Novel Coronavirus Pneumonia (COVID-19) in the recovery period; 2. Patients with fatigue, anorexia, abdominal distension, loose stools and other digestive dysfunction as the main clinical manifestations, 3 of them at the same time, or a single symptom visual analog score (VAS) greater than 5 points; 3. Heal patients who have been discharged for more than 2 weeks; 4. Aged 18-70 years old; 5. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with fatigue, anorexia, abdominal distension, loose stools due to other reasons or diseases of the digestive system; 2. Patients with difficulties in taking oral drugs due to underlying diseases and other reasons; 3. It is accompanied by serious basic diseases that affect survival, including uncontrolled clinically meaningful heart, lung, kidney, digestion, blood disease, neuropsychiatric disease, immune disease, metabolic disease, malignant tumor, severe malnutrition, etc ; 4. People with allergies and allergies to the drugs involved in the treatment plan; 5. Women during pregnancy or lactation; 6. Those who cannot cooperate with their mental state, those who suffer from mental illness, lack self-control, and cannot express clearly; 7. Those who are participating in other clinical trials; 8. According to the judgment of the investigator, there will be patients who are complicated to enroll or have poor compliance, etc., which affect the efficacy and safety evaluation.

Design outcomes

Primary

MeasureTime frame
Changes in the degree of clinical symptoms such as fatigue, poor appetite, abdominal distension, and loose stools caused by decreased digestive function of the two groups of subjects;

Countries

China

Contacts

Public ContactPeng Bo

Wuhan Third Hospital

1530424244@qq.com+86 17762539690

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026